ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lundblad, R.
Right arrow Articles by Fosse, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lundblad, R.
Right arrow Articles by Fosse, E.

Ann Thorac Surg 1997;63:1361-1367
© 1997 The Society of Thoracic Surgeons


Original Article: Cardiovascular

Endothelin-1 and Neutrophil Activation During Heparin-Coated Cardiopulmonary Bypass

Runar Lundblad, MD, PhD, Oddvar Moen, MD, PhD, Erik Fosse, MD, PhD

Department of Cardiothoracic Surgery, Ullevaal Hospital, Oslo, Norway

Accepted for publication December 6, 1996.

Background. Heparin-coated circuits attenuate the systemic inflammatory response to cardiopulmonary bypass. The present study compares two different heparin coatings in terms of the release of endothelin-1 and neutrophil glycoproteins.

Methods. Forty low-risk patients undergoing coronary artery bypass grafting were investigated, having cardiopulmonary bypass with a Duraflo II heparin-coated circuit (n = 10), an identical but uncoated circuit (n = 10), a Carmeda BioActive Surface heparin-coated circuit (n = 10), or an identical but uncoated circuit (n = 10). A standard systemic heparin dosage was used in all patients. Endothelin-1 and the neutrophil glycoproteins lactoferrin and myeloperoxidase were quantified throughout the operation and 3 hours postoperatively.

Results. Enhanced plasma levels of endothelin-1, lactoferrin, and myeloperoxidase were observed during and after uncoated cardiopulmonary bypass, but this was not associated with clinical side effects. Compared with the respective uncoated controls, Duraflo II attenuated only the lactoferrin levels, whereas Carmeda BioActive Surface was associated with lower levels of both endothelin-1, lactoferrin, and myeloperoxidase. Of the two heparin coatings, Carmeda BioActive Surface proved more effective than Duraflo II in attenuating the levels of these substances.

Conclusions. The plasma levels of endothelin-1, lactoferrin, and myeloperoxidase increase during cardiopulmonary bypass in coronary artery bypass grafting, but this has no clinical side effects in low-risk patients. The increase is attenuated using heparin-coated extracorporeal circuits, and then more effectively by Carmeda BioActive Surface than by Duraflo II.




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. Taneja and D. C. Cheng
Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures
Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372.
[Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
S. G Raja and G. D Dreyfus
Modulation of Systemic Inflammatory Response after Cardiac Surgery
Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
S. W Sutton, M. A Duncan, V. A Chase, B. L Hamman, and E. H Cheung
Perfusion-assisted beating heart support with a miniature extracorporeal circuit and leukocyte filtration: a 58-year-old patient with severe COPD
Perfusion, December 1, 2004; 19(6): 369 - 373.
[Abstract] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
C. Weissman
Pulmonary Complications After Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2004; 8(3): 185 - 211.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari
A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit
Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
H. I Flom-Halvorsen, E Ovrum, F Brosstad, G Tangen, M A. Ringdal, and R Oystese
Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction
Perfusion, September 1, 2002; 17(5): 339 - 345.
[Abstract] [PDF]


Home page
PerfusionHome page
D. A Palanzo, D. L Zarro, N. J Manley, R. M Montesano, M. Quinn, B.-A. Elmore, P. A Gustafson, and J. M Castagna
Effect of Carmeda(R) BioActive Surface coating versus TrilliumTM Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass
Perfusion, July 1, 2001; 16(4): 279 - 283.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad
Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330.
[Abstract] [Full Text] [PDF]


Home page
J Biomater ApplHome page
N. Weber, H. P. Wendel, and G. Ziemer
Quality Assessment of Heparin Coatings by their Binding Capacities of Coagulation and Complement Enzymes
J Biomater Appl, July 1, 2000; 15(1): 8 - 22.
[Abstract] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. P. Wendel and G. Ziemer
Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation
Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. OTTOSSON-SEEBERGER, G. AHLBORG, A. HEMSÉN, J. M. LUNDBERG, and A. ALVESTRAND
Hemodynamic Effects of Endothelin-1 and Big Endothelin-1 in Chronic Hemodialysis Patients
J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1037 - 1044.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
A. L. Picone, C. J. Lutz, C. Finck, D. Carney, L. A. Gatto, A. Paskanik, B. Searles, K. Snyder, and G. Nieman
Multiple sequential insults cause post-pump syndrome
Ann. Thorac. Surg., April 1, 1999; 67(4): 978 - 985.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J.-P. Carteaux, S. Roux, M. Siaghy, B. Schjoth, P. Dolofon, Y. Bechamps, P. M. Mertes, and J.-P. Villemot
Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin
Eur. J. Cardiothorac. Surg., March 1, 1999; 15(3): 346 - 352.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
H. P Wendel, A. M Scheule, F. S Eckstein, and G. Ziemer
Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces
Perfusion, January 1, 1999; 14(1): 21 - 28.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 by The Society of Thoracic Surgeons.